EE360 Health Care Resource Utilization With Asciminib and Bosutinib Among Adults With Chronic Myeloid Leukemia in Chronic Phase Previously Treated With ≥2 Tyrosine Kinase Inhibitors: Week 48 and Week 96 Results From ASCEMBL Trial
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.606
https://www.valueinhealthjournal.com/article/S1098-3015(22)02810-8/fulltext
Title :
EE360 Health Care Resource Utilization With Asciminib and Bosutinib Among Adults With Chronic Myeloid Leukemia in Chronic Phase Previously Treated With ≥2 Tyrosine Kinase Inhibitors: Week 48 and Week 96 Results From ASCEMBL Trial
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02810-8&doi=10.1016/j.jval.2022.09.606
First page :
Section Title :
Open access? :
No
Section Order :
10138